SCNI vs TLRY · P/E 0.2, rev $1.3M vs rev $915.5M
Scinai Immunotherapeutics Ltd (SCNI) versus Tilray Inc (TLRY) — a side-by-side from cached financials, not a winner call.
Scinai Immunotherapeutics Ltd (SCNI) is a biotechnology company listed on NASDAQ.
Tilray Inc (TLRY) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported SCNI revenue for 2025-12-31 was $1.3M. Net income was -$8.3M. Revenue was up 99.2% from 2024-12-31 to 2025-12-31. SCNI currently screens at market cap $1.8M and trailing P/E 0.2.
Latest reported TLRY revenue for 2026-05-31 was $915.5M. Net income was -$121.4M. Revenue was up 11.5% from 2025-05-31 to 2026-05-31. TLRY currently screens at market cap $573.9M.
SCNI currently screens at market cap $1.8M and trailing P/E 0.2. TLRY currently screens at market cap $573.9M.
Not investment advice. Open the SCNI and TLRY stock pages for the full models.
Not investment advice.